Tag Archives: patients

Spending on Medicines In and Post-COVID Say a Lot About Patients and Larger Healthcare Trends – an IQVIA Update

Spending on medicines, globally, will rebound this year and rise above pre-pandemic levels through 2025. Between 2021 and 2025, the annual growth global growth rate for prescription drugs spending is expected to range from 3% to 6%, a $ 1.6 trillion bill for the worlds’s total Rx medicines market. That relatively low single-digit growth rate… Read More »

FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis

FDA Approves Bronchitol (mannitol) Inhalation Powder to Improve Pulmonary Function in Adult Patients with Cystic Fibrosis CARY, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) — Chiesi USA, Inc., the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), received U.S. Food and Drug Administration (FDA) approval of Bronchitol (mannitol) inhalation powder. Bronchitol… Read More »

Flexible Skin Sensor to Help ALS Patients Communicate

Researchers at MIT have developed a wearable sensor that can detect small deformations of the skin, potentially serving as a way to help amyotrophic lateral sclerosis (ALS) patients to communicate through facial movements. The low-cost sensors are much cheaper and may be more effective than current assistive communication technologies for ALS patients. Canan Dagdeviren, the… Read More »

Berry liquid diet elderly patients

Mayo Clin Proc. Refeeding syndrome is underdiagnosed and undertreated, but treatable. The best option for treating malnutrition is to enhance normal eating and drinking. Z Gerontol Geriat. A Cuisinart or blender is the most essential tool for a liquid or soft diet. The onset of nutritional problems is often gradual and therefore hard to detect.… Read More »

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy

FDA Approves Viltepso (viltolarsen) for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy Print this page PARAMUS, N.J., Aug. 12, 2020 /PRNewswire/ — NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has approved Viltepso (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who… Read More »